Gout is a metabolic-inflammatory joint disease caused by the deposition of monosodium urate (MSU) crystals in the joints. Its pathological basis is hyperuricemia (HUA, defined as fasting serum uric acid >420 µmol/L on two separate occasions) resulting from purine metabolism disorders and/or reduced uric acid excretion. Based on the different mechanisms underlying the occurrence of hyperuricemia, g
Conditions
Interventions
Febuxostat group:urate-lowering therapy(Febuxostat )
Dotinurad group:urate-lowering therapy(Dotinurad)
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with gout according to the 2015 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for gout, and judged by the investigator to require long-term urate-lowering therapy. 2. Aged between 18 and 70 years. 3. The clinical type of hyperuricemia is combined type, defined as a 24-hour urinary uric acid excretion (UUE) > 600 mg and a fractional excretion of uric acid (FEUA) = 420 µmol/L (7.0 mg/dL), plus one of the following comorbidities: 1) >=2 gout flares per year 2) Tophus 3) Chronic gouty arthritis 4) Hypertension 5) Diabetes mellitus 6) Dyslipidemia 7) Age at onset = 480 µmol/L (8.0 mg/dL) without the above comorbidities. 5. Body mass index (BMI) between 18.0 and 35.0 kg/m^2 (inclusive). 6. Fully understand the trial content, voluntarily participate in the trial, are able to complete the trial procedures, and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Transaminase levels more than twice the upper limit of normal. 2. Estimated glomerular filtration rate (eGFR) <= 45 mL/min/1.73 m^2. 3. Need to take any other uric acid-lowering drugs or other drugs that affect serum uric acid levels. 4. With a history of acute gout attack within 2 weeks before enrollment. 5. Severe kidney stones, obstructive nephropathy, severe heart disease (NYHA classification grade 1 or above), or severe cerebrovascular disease. 6. Refuse to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of achieving target serum uric acid level;Height; | — |
Countries
China
Contacts
Public ContactChen Ying
The Affiliated Hospital of Qingdao University
Outcome results
None listed